Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Neurogenic Detrusor Overactivity and Urinary Incontinence
NCT01091727Phase 3Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2006
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in neurogenic detrusor overactivity (NDO) and urinary incontinence (UI), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Efficacy at 36 weeks. Started Oct 2006; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic detrusor overactivity (NDO)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT01091727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01091727.